ProMIS Neurosciences provided an update from a preclinical study comparing PMN310 to other amyloid beta-directed antibodies combating Alzheimer’s disease.
ProMIS Neurosciences (TSX:PMN) provided an update from a preclinical study comparing PMN310 to other amyloid beta-directed antibodies combating Alzheimer’s disease.
As quoted in the press release:
[ProMIS’] lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD).
Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer’s disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers.”